Health
Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study – News-Medical.Net
A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2…
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, has spread to over 58.8 million worldwide and caused over 1.3 million deaths. The rush to develop safe and effective vaccines to prevent the ongoing spread of SARS-CoV-2 is nearing the finish line as several promising candidates await regulatory body approval for widescale distribution and use.
A team of researchers from the USA and China have engineered a…
-
Business20 hours agoWarning! These ASX 200 shares were just downgraded
-
Business13 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Business10 hours agoTop brokers name 3 ASX shares to buy today 27 August 2025
-
Business13 hours agoThis ASX 200 media stock is storming 7% higher to 52-week highs. Here’s why.